400 related articles for article (PubMed ID: 31718453)
1. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
[TBL] [Abstract][Full Text] [Related]
2. [Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer].
Shimada S; Kuroiwa K; Narita H; Okamura R; Uesugi Y; Sasaki Y; Watanuki M; Arai N; Kawaguchi Y; Fujiwara S; Yanagisawa K; Hattori N
Rinsho Ketsueki; 2024; 65(1):24-29. PubMed ID: 38311385
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy.
Gergi M; Landry KK; Ades S; Barry M; Zakai NA; Herrera DA
Oncologist; 2020 Dec; 25(12):1009-1012. PubMed ID: 33017484
[TBL] [Abstract][Full Text] [Related]
4. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy.
Lancelot M; Miller MJ; Roback J; Stowell SR
Transfusion; 2021 Jan; 61(1):322-328. PubMed ID: 33119913
[TBL] [Abstract][Full Text] [Related]
5. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
[TBL] [Abstract][Full Text] [Related]
6. Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by Influenza A (H1N1) Virus Successfully Treated by Plasma Exchange: A Case Report.
Kubo K; Abe T; Kawano N; Ochiai H
Am J Case Rep; 2021 Aug; 22():e932251. PubMed ID: 34334786
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.
Nelson D; Kodsi M; Cockrell D; Morgan J; Key N
J Oncol Pharm Pract; 2022 Jun; 28(4):979-982. PubMed ID: 35037788
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Suliman AM; Bek SA; Elkhatim MS; Husain AA; Mismar AY; Eldean MZS; Lengyel Z; Elazzazy S; Rasul KI; Omar NE
Cancer Immunol Immunother; 2021 Apr; 70(4):935-944. PubMed ID: 33070259
[TBL] [Abstract][Full Text] [Related]
10. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.
Bourdin V; Fossé Q; Lambotte O; Joly B; Coppo P; Anguel N; Labeyrie C
Br J Haematol; 2024 Apr; 204(4):1459-1463. PubMed ID: 38112161
[TBL] [Abstract][Full Text] [Related]
12. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G
Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340
[TBL] [Abstract][Full Text] [Related]
13. Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy.
Kozak M; Rubenstein W; Okwan-Duodu D; Friedman K; Nassir Y; Perez-Alvarez I; Gibb DR; Klapper E; Pepkowitz S
Transfusion; 2023 Jun; 63(6):1241-1245. PubMed ID: 37096845
[TBL] [Abstract][Full Text] [Related]
14. Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP.
Bayraktar S; Eileen B; Shariatmadar S; Lian E
BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22798444
[TBL] [Abstract][Full Text] [Related]
15. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.
Yarranton H; Machin SJ
Curr Opin Neurol; 2003 Jun; 16(3):367-73. PubMed ID: 12858075
[TBL] [Abstract][Full Text] [Related]
16. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.
Al-Husban N; Al-Kuran O
J Med Case Rep; 2018 Jun; 12(1):147. PubMed ID: 29855343
[TBL] [Abstract][Full Text] [Related]
17. Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature.
Lin HC; Huang J; Huang J; Zhang LJ; Yin XW; Yang JC; Huang XY
J Med Case Rep; 2023 Feb; 17(1):38. PubMed ID: 36750960
[TBL] [Abstract][Full Text] [Related]
18. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
Fu S; Wang T; Xu F
J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
[TBL] [Abstract][Full Text] [Related]
19. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an Asian woman: a case report.
Ge H; Shi Z; Zheng Z; Zhu Q; Hong L; Zhang Y; Shen J; Deng S
J Int Med Res; 2022 Mar; 50(3):3000605221085127. PubMed ID: 35352601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
